Alex Philippidis

3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies Ocugen says it is on track to reshape the market for gene therapies against eye disorders over the next three years, by working to bring to market three treatments for blindness-related diseases, two ...

6August: How does Ocugen ( $OCGN ) expect OCU410 to stand out among geographic atrophy treatments when two such drugs have entered the market in recent years, bolstered by saturation ad campaigns? Hear from CEO Shankar Musunuri, PhD, in my latest for GEN: www.genengnews.com/topics/genom...

10.08.2025 05:22 — 👍 1    🔁 0    💬 0    📌 0

Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions” Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary roundtable conducted by the FDA in front of its recently-appointed top offi...

6May: What personal stories and policy recommendations did cell and gene therapy leaders share with officials from the @fda.gov, NIH, CMS, and HHS? Colleague and editor @kevinadavies.bsky.social and I recap Thursday's historic FDA roundtable in GEN: www.genengnews.com/topics/genom...

06.06.2025 05:39 — 👍 0    🔁 0    💬 0    📌 0

Illumina Sues Element Biosciences, Alleging Infringement of Flow Cell, Imaging Patents Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are reviewing the complaint and look forward to defending our innovations in cou...

19May: What is Illumina demanding of Element Biosciences in a patent infringement lawsuit filed Thursday? And how is Element responding? One of my latest for GEN: www.genengnews.com/topics/omics...

20.05.2025 14:10 — 👍 0    🔁 0    💬 1    📌 0

Giving away translations of some of my books — please get in touch if interest:

- Breakthrough (1995) 🇬🇧
- Cracking the Genome (2001) 🇯🇵🇵🇹🇪🇸🇳🇱🇨🇿🇩🇪🇸🇪🇮🇹🇸🇦
- The $1,000 Genome (2010) 🇰🇷🇧🇷
- Editing Humanity (2020) 🇰🇷🇷🇺🇯🇵🇮🇹

03.05.2025 12:08 — 👍 2    🔁 2    💬 0    📌 0

27April: Thanks to BioHealth Innovation's Rich Bendis and his BioTalk podcast for inviting me back to discuss the convulsive policy shifts and resulting impacts on biotech business and investment activity. Listen here or wherever you get podcasts: www.youtube.com/watch?v=nft8...

27.04.2025 17:52 — 👍 0    🔁 0    💬 0    📌 0

FDA, NIH, CDC Stagger as HHS Axe Falls, Eliminating 10,000 Jobs The 10,000 jobs being eliminated include 3,500 positions at the FDA, 2,400 at the U.S. Centers for Disease Control and Prevention (CDC), and 1,200 at the NIH.

2April: Rounding up the darkest day for the federal agencies at the center of #biotech ... My latest for GEN:
www.genengnews.com/topics/drug-...

02.04.2025 05:19 — 👍 0    🔁 0    💬 0    📌 0

StockWatch: Will Trump Tariffs Return Biopharma Manufacturing to the U.S.? With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry leaders, market watchers, and others have begun assessing which companies will ...

31March: Will Trump's planned tariffs return biopharma manufacturing to the U.S.? Which companies did Jefferies say were most and least exposed if these tariffs take effect? Also, updates on $ATNA, $SAVA, $EQ, & $MURA in my latest StockWatch for GEN: www.genengnews.com/topics/biopr...

31.03.2025 13:42 — 👍 1    🔁 0    💬 0    📌 0

Industry Voices Alarm as Peter Marks Departs FDA The sudden departure of Peter Marks, MD, from the FDA has prompted a chorus of criticism and despair from industry leaders and trade organizations.

31March: How have #biotech industry groups, an analyst, some research leaders and others addressed the surprising departure of Peter Marks, MD, from the FDA? Colleague and editor @kevinadavies.bsky.social and I summed up the responses for GEN: www.genengnews.com/topics/drug-...

31.03.2025 05:26 — 👍 1    🔁 0    💬 0    📌 0

31March: Howdy BlueSky... The plural of which is Blue Skies. Ella can take it from here....
www.youtube.com/watch?v=SAa4...

31.03.2025 05:23 — 👍 0    🔁 0    💬 0    📌 0